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Background:  Community-acquired pneumonia (CAP) is the most common infectious cause of 
death in the United States. To understand the impact of efforts to improve quality and efficiency 
of care in CAP, we examined trends in mortality and costs among hospitalized CAP patients. 
 
Methods: Using the National Inpatient Sample from 1993–2005, we studied 569,524 CAP 
admissions. The primary outcome was mortality at discharge. We used logistic regression to 
evaluate the mortality trend, adjusting for age, gender, and comorbidities. To account for the 
impact of early discharge practices, we also compared daily mortality rates and performed a Cox 
proportional-hazards model. We used a generalized linear model to analyze trends in 
hospitalization costs, which were derived using cost-to-charge ratios. 
 
Results:  Over time, length of stay (LOS) declined, while more patients were discharged to other 
facilities. The frequency of many comorbidities increased. Age/gender-adjusted mortality 
decreased from 8.9% to 4.1% (P < 0.001). In multivariable analysis, the mortality risk declined 
through 2005 (odds ratio, 0.50; 95% confidence interval [CI], 0.48–0.53), compared to reference 
year 1993. The daily mortality rates demonstrated that most of the mortality reduction occurred 
early during hospitalization. After adjusting for early discharge practices, the risk of mortality 
still declined through 2005 (hazard ratio, 0.74, 95% CI 0.70–0.78). Median hospitalization costs 
exhibited a modest reduction over time, mostly due to reduced LOS. 
 
Conclusions:  Mortality among patients hospitalized for CAP has declined. Lower in-hospital 
mortality at a reduced cost suggests that pneumonia is a case of improved productivity in health 
care.   4 
INTRODUCTION 
    Community-acquired pneumonia (CAP) is the most common infectious cause of death in the 
United States. Hospitalization rates for CAP have increased, as have comorbidities among these 
patients.
1 The substantial treatment costs of CAP were estimated at $12.2 billion during the late 
1990s,
2 with additional costs in lost productivity.
3  
 
     There has been a great deal of research on measures to improve the quality and efficiency of 
care for CAP patients.
4, 5 Pneumococcal vaccination (PV), influenza vaccination (IV), 
combination antibiotic therapy, early antibiotics, and obtaining blood cultures are associated with 
reduced mortality.
6-9 These process measures are being used as quality indicators by the Centers 
for Medicare and Medicaid Services’ Hospital Compare quality initiative, and will likely be 
increasingly linked to payments.
10 
 
     Despite these efforts, the impact of more widespread use of these interventions on mortality 
has not been measured. Especially with increasing hospitalization rates, it is important to 
understand trends in mortality, length of stay (LOS), and costs of care for community 
populations.  We therefore examined these trends in hospitalized CAP patients. 
 
METHODS 
     Our analysis used hospitalizations from a 10% subsample of the Healthcare Cost and 
Utilization Project’s National Inpatient Sample (NIS) from 1993–2004, as well as the full sample 
from 2005, for which no subsample is provided. This nationally representative, all-payer 
Data Source, Study Population, and Data Elements   5 
database has been described elsewhere.
11 Hospitalizations for CAP in patients aged ≥ 18 years 
were identified using International Classification of Diseases, Ninth Revision, Clinical 
Modification codes recorded at discharge. A hospitalization met the diagnostic criteria by either a 
principal diagnosis of pneumonia (codes 481–486) or a principal diagnosis of respiratory distress 
(code 786) or respiratory failure (code 518) with a secondary pneumonia diagnosis. This code 
combination has an 84% sensitivity and 86% specificity, compared to clinical chart review.
12 
 
     Patient age, sex, admission source, discharge diagnoses, LOS, total charge, and discharge 
disposition were obtained from the record of each applicable hospitalization. Using the 
Elixhauser AHRQ Comorbidity Software, 29 binary comorbidity indicator variables (CIVs) were 
defined based on the discharge diagnoses.
13 
 
     We performed additional analyses to account for the potential impact of changing admission, 
discharge, and coding practices. There has been increased on-site treatment of long-term care 
(LTC) facility residents who develop pneumonia.
14 Since this subgroup has a very high mortality 
rate, a trend toward on-site treatment might artifactually decrease mortality among hospitalized 
patients. The NIS does not capture patients treated at LTC facilities without transfer to an acute-
care hospital. Therefore, to assess for the sensitivity of our results to more frequent on-site 
treatment, we performed an analysis eliminating all patients admitted from a LTC facility. There 
has also been a trend toward earlier hospital discharge and transfer to skilled nursing facilities 
(SNFs) and intermediate care facilities (ICFs), as well as discharge with home health care 
(HHC).
15 Finally, the number of fields available for coding diagnoses has increased, resulting in   6 
more frequent coding of comorbidities. We describe below analyses to assess the sensitivity of 
our results to these factors. 
 
     Costs were calculated from hospital charges, using cost-to-charge ratios (CCRs) provided by 
AHRQ.
16, 17 CCRs were not available for all hospitals in all years. We therefore used a 
prioritization scheme (details in the appendix) to estimate each hospital’s CCR. If a hospital-
specific CCR was unavailable for a particular year, the hospital-specific CCR from a proximate 
year was used. In such cases, per AHRQ recommendations, a 3% increase or decrease in the 
CCR was applied when going backward or forward in time, respectively.
16 If a hospital-specific 
CCR was unavailable, we used the hospital group average CCR, which is a weighted average for 
hospitals in the group, defined based on state, urban/rural location, investor-owned/other, and 
number of beds. If this group average was also unavailable, we used the average CCR in the 
hospital’s NIS stratum, which is assigned based on region, ownership type, urban/rural location, 
teaching/nonteaching status, and number of beds. CCRs were not available for 1993–1996, and 
1998, so these were imputed based on 1997 and 1999 CCRs with the aforementioned 3% 
adjustment. Hospitalization cost was calculated by multiplying total charge by the CCR. The 
costs were then adjusted for inflation to year 2000 dollars using the general Consumer Price 
Index. Cost per hospital day was calculated by dividing cost by LOS. Charges were missing for 
9790 (1.72%) of hospitalizations. We were unable to establish a CCR for 4079 (0.72%) of the 
hospitalizations. As a result of a missing charge or CCR, cost was missing for 11635 (2.04%) of 
the hospitalizations, which were eliminated from the cost analyses. 
 
Statistical Analysis   7 
     Summary statistics of patient and hospitalization characteristics were calculated. Statistical 
significance of the annual trend was assessed using the Mantel-Haenszel chi-square test for trend. 
We report composite data for 1993–1995 and 2003–2005, treating each as a single observation. 
Our first analysis presents trends in mortality rate, adjusted for the age (by decade) and gender 
composition of the reference year (1993) hospitalizations. 
 
     Previous research has shown a biased coding of certain comorbidities.
18  In particular, coding 
of six of the Elixhauser CIVs have paradoxically been associated with reduced mortality risk.
19 
We therefore estimated univariate logistic regressions of mortality on these CIVs to ascertain 
potential for coding bias. Of these six, the three associated with a lower risk of mortality 
(depression, drug abuse, and obesity) were excluded from subsequent analyses. 
 
     Multivariate logistic regression was then performed, estimating the likelihood of death. Our 
primary outcome measure was the adjusted odds ratio (OR) of in-hospital death in each year 
relative to 1993. The primary analysis regressed survival on categorical variables for each year, 
age-sex by 10-year age categories, and 26 CIVs. To assess for the impact of changing admission 
and coding practices, this regression was repeated (a) excluding patients admitted from LTC 
facilities; and (b) after restricting patients in all years to a maximum of five total discharge 
diagnoses. 
 
    Since the trend toward a shorter LOS reduces the duration of observation, we also calculated 
the daily mortality rate – the proportion of patients still hospitalized who died on each day. 
Additionally, a multivariate Cox proportional-hazards model was used to estimate the trend in   8 
mortality, accounting for the censoring that early discharge creates. The daily mortality rate 
became disproportionately higher among the 25% of hospitalizations greater than one week, 
likely reflecting selection based on poor health and/or severe disease. Because of this 
disproportionality, all patients were censored at a LOS of 7 days for the hazard model. 
 
     To analyze costs, we calculated the annual median hospitalization cost and median cost per 
hospital day. We also performed two generalized linear model (GLM) regressions to analyze cost 
trends, both of which specified cost as the dependent variable, using a gamma distribution and 
log link function.
20 Due to a non-random pattern of residuals in the highest-cost 1% of 
hospitalizations, this 1% was eliminated from the analyses. Both regressions included the same 
independent variables as the primary mortality regression described above. The second GLM 
regression additionally included LOS as an independent variable to ascertain how much of the 
cost trend might be attributable to changes in LOS. 
 
     All statistical analyses were performed using Statistical Analysis Software, version 9.1 (SAS; 
SAS Institute Inc., Cary, NC). 
 
RESULTS 
     We identified 569,524 patients who met the coding criteria for CAP. As Table 1 illustrates, 
comparison of hospitalization subsets in two periods shows that mean LOS declined from 7.5 
to 5.7 days, while the proportion of patients discharged to a SNF/ICF or with HHC increased. 
Figure 1 exhibits the trend in several common comorbidities. 
   9 
     Table 1 demonstrates that mortality rates declined across age-categories. Figure 2A shows the 
mortality trend, adjusted for age and gender, which declined from 8.9% to 4.1% (P < 0.001). 
Figure 2B demonstrates the results of the multivariate-adjusted logistic regressions (complete 
results in the appendix). The OR of death declined to 0.50 (95% CI 0.48–0.53) in 2005. The 
results of the regression excluding patients admitted from LTC facilities (OR2005 = 0.50) were 
very similar to the primary regression. After restricting all patients to a maximum of five 
diagnoses, the OR2005 was 0.51. 
 
     The daily mortality risk is shown in Figure 3, which demonstrates that the mortality rate on 
any given day early in the hospitalization is lower in 2004/2005 compared to 1993/1994. The 
hazard ratio of mortality in 2005 was 0.74 (95% CI 0.70–0.78), suggesting a 26% lower 
multivariate-adjusted risk of mortality, accounting for the censoring created by early discharge. 
 
     Figure 4 shows that, over the study period, median hospitalization costs (based on 557,889 
hospitalizations) declined from $5473 to $4913, while median costs per hospital day increased 
from $868 to $1154. It also shows the results of the multivariate-adjusted GLM cost regressions, 
which calculate adjusted, mean predicted costs. The predicted mean cost of hospitalization in 
2005 is $1017 less than in 1993. As is suggested by the increase in median per day costs, when 
also adjusted for LOS, the predicted cost of hospitalization in 2005 is $1200 higher than in 1993. 
 
DISCUSSION 
     Studies have shown the benefit of several interventions in improving the outcomes of CAP 
patients.
21 Despite this, our study is the first to assess trends in outcomes and costs over many   10 
years using a large, nationally-representative database. Until fairly recently, the mortality risk 
associated with CAP was high. For reference, a 1982 Lancet report studying CAP patients (mean 
age 51) showed an in-hospital mortality rate of 15%.
22 A prospective study conducted from 1981 
to 1987 showed a mortality rate of 28.6% among elderly hospitalized pneumonia patients.
23 Our 
analysis reveals a marked mortality reduction over time among a large sample of hospitalizations 
for CAP. Further, adjusted costs were lower at the end of the period than at the beginning.  
These findings support the assertion that pneumonia care is a case of improved productivity – 
better health at lower spending. 
 
     This study shows improvement in outcomes for pneumonia patients, as an increasing 
incidence makes this a public health priority. We also demonstrate that outcomes of CAP 
patients have improved despite an increasing comorbidity burden. Moreover, this improvement 
occurred during a time when a trend toward outpatient treatment might make hospitalized 
patients sicker in ways we cannot measure. 
 
     Several factors may explain the mortality reduction. Improvements in critical care have likely 
impacted pneumonia outcomes.
24, 25 PV has little effect on incidence, but decreases mortality 
through reduced rates of bacteremia and invasive pneumococcal disease.
8, 26, 27 IV has also been 
associated with a lower mortality among hospitalized CAP patients.
9 The Behavior Risk Factor 
Surveillance System reports that from 1993 to 2005, the percent of elderly adults who received 
PV and IV increased from 27.8% to 65.9% and from 50.9% to 65.7%, respectively.
28  Guideline-
concordant, combination antibiotic therapy reduces mortality compared to monotherapy.
6, 29, 30 
One study found that three broad-spectrum antibiotic regimens reduced mortality with hazard   11 
ratios of 0.64 to 0.71.
31 Data from the early 1990s showed that only 54-64% of CAP patients 
received broad-spectrum antibiotics.
32, 33 Recent Community-Acquired Pneumonia Organization 
data showed that 88% received such therapy.
34 Although less likely to explain the mortality trend, 
early antibiotics and obtaining blood cultures have also been associated with reduced mortality.
7 
Since NIS data does not include specific antibiotic information or patients’ vaccination history, 
we cannot definitively determine the reasons for the identified trends. However, based on the 
referenced literature, we posit that more widespread use of these interventions has achieved 
substantial benefit among CAP patients. 
 
     Our findings on hospitalization costs are consistent with other literature showing that reduced 
LOS with higher daily costs are keeping hospitalization costs relatively constant over time.
35, 36 
Over the study period, our data revealed a 32% increase in median daily costs. Our calculated 
median hospitalization and daily costs in the reference year 1993 of $5473 and $868, 
respectively, are similar to the $5942 and $836 found in the Pneumonia Patient Outcomes 
Research Team cohort study, conducted from 1991 through 1994.
37 This concordance suggests 
that the AHRQ-recommended cost imputation methods produced accurate results. Greatly 
reduced mortality at a lower cost suggests a productivity improvement and increase in the value 
of CAP-related expenditures over time. Furthermore, Our GLM regression results suggest that 
LOS has been the major identifiable mechanism by which costs have declined. 
 
     This study is limited to capturing in-hospital mortality, without 30-day mortality or 
readmission rates. With a decreased LOS, more patients were discharged to other facilities. 
Reduced LOS might artifactually decrease the in-hospital death rate among those patients   12 
discharged early. It is therefore possible that more deaths occurred after discharge in recent years. 
However, the hazard model, which accounted for the censoring of early discharge, also shows a 
large improvement over time. We also show a marked reduction in the daily mortality risk early 
in the hospitalization, during which time comparisons would be less sensitive to changing 
discharge practices. Moreover, one study showed that readmission rates, as well as post-
discharge and 30-day mortality rates, did not differ among hospitals despite significant variation 
in LOS.
38 While this study evaluated the relationship of mortality rates and cross-sectional 
(rather than longitudinal) variation in LOS, it does suggest that physicians’ judgment about 
criteria for early discharge does not compromise post-discharge outcomes. Our study is also 
limited by the absence of physiologic indicators necessary to calculate a pneumonia severity 
index (PSI). However, it is likely that the patients admitted in recent years are, on average, 
physiologically sicker than those admitted in early years. Therefore, we believe that inclusion of 
a PSI would not diminish the demonstrated improvement. It is also possible that a portion of the 
increased frequency of comorbid conditions is due to changes in coding practices and the 
increased number of coding fields. However, this finding is consistent with other studies of 
hospitalized pneumonia patients.
1  Demographics and improved survivorship of patients with 
other illnesses, such as cardiac disease, may be contributing to the increasing hospitalization 
rates for CAP. Furthermore, much of the improved survival we demonstrate was already evident 
before adjusting for comorbidities. 
 
     While we examine the costs of hospital care for CAP, we do not account for the costs of post-
acute care. However, research suggests that site-of-care substitution results in post-acute care 
costs much less than the savings achieved through reduced LOS.
36 Another study showed that   13 
the mean post-acute care costs for the 40% of hospitalized pneumonia patients who received any 
post-acute care was $1100.
15 In our study, the percentage of patients who were either discharged 
to a SNF/ICF or with HHC increased from 27.7% in the early years to 34.6% in recent years. 
Extrapolating this 6.9% increase to our study population with a mean $1100 per discharge would 
increase the average cost per hospitalization by only $76, an amount which would not change our 
conclusions. Moreover, post-acute care has been shown to decrease the total costs of an episode 
of illness by reducing the readmission rate.
39 It is therefore possible that, despite additional direct 
costs, greater use of post-acute care would decrease the total cost of a CAP episode. While we 
do not know with certainty the effect that site-of-care substitution would have on cost 
trends, we believe that our analysis provides qualified evidence of improved productivity. 
 
     In sum, while numerous studies have shown the benefit of several interventions in improving 
pneumonia outcomes, ours is the first study to demonstrate a reduction in mortality risk over 
time based on a large, national dataset. Caregivers should be encouraged by our study results, 
which suggest that their efforts have greatly decreased the risk of mortality posed by the 
“Captain of the Men of Death.” 
 
Additional Information:  The appendix is available at http://journals.lww.com/lww-
medicalcare/pages/default.aspx 
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Figure Legends 
 
 
Figure 1.  Selected comorbidities of patients hospitalized for community-acquired pneumonia. 
Error bars indicate 95% confidence intervals. CHF denotes congestive heart failure; DM denotes 
diabetes mellitus. 
 
Figure 2.  Mortality trends adjusted for age and sex (A) and multivariable-adjusted odds ratio of 
death relative to the reference year 1993 (B). The multivariate model is adjusted for age, sex, and 
comorbid conditions. Error bars indicate 95% confidence intervals. LTC denotes long term care.  
 
Figure 3.  Daily mortality rates for 1993/1994 and 2004/2005 among patients still hospitalized 
on each hospital day. Error bars indicate 95% confidence intervals. 
 
Figure 4.  Trends in median hospitalization costs, total and per hospital day. The trend in 
predicted mean costs is based on a generalized linear model that specified cost as the dependent 
variable and age, sex, and comorbid conditions as covariates. One model also included length of 
stay (LOS).   18 
TABLE 1.  Patient and Hospitalization Characteristics in Two Selected Periods among 
Patients Hospitalized for Community-Acquired Pneumonia 
 
 
 
  1993 – 1995 
(n = 104,491) 
  2003 – 2005 
(n = 277,916) 
    P 
Age, by category (years)         
18 – 29 (%)  4,371 (4.2)    7,346 (2.6)  <.001 
30 – 39 (%)  7,562 (7.2)    10,859 (3.9)   
40 – 49 (%)  7,589 (7.3)    21,431 (7.7)   
50 – 59 (%)  8,771 (8.4)    31,516 (11.3)   
60 – 69 (%)  16,278 (15.6)    44,176 (15.9)   
70 – 79 (%)  26,848 (25.7)    66,886 (24.1)   
80 – 89 (%)  25,290 (24.2)    71,990 (25.9)   
90 – 99 (%)  7,514 (7.2)    22,918 (8.2)   
100 + (%)  268 (0.3)    794 (0.3)   
         
Female, n (%)  50,434 (48.3)    148,426 (53.4)  <.001 
         
Mean Length of Stay, Days  7.5    5.7  <.001 
         
Admitted from long-term care 
facility, n (%) 
4,598 (4.4)    6,114 (2.2)  <.001 
Discharged to skilled nursing or 
other facility, n (%) 
19,644 (18.8)    64,754 (23.3)  <.001 
Discharge with home health 
care, n (%) 
9,299 (8.9)    31,405 (11.3)  <.001 
         
Mortality, overall, n (%)  8,827 (8.4)    13,133 (4.7)  <.001 
Mortality, by age category         
18 – 29 (%)  65 (1.5)    88 (1.2)   
30 – 39 (%)  241 (3.2)    114 (1.0)   
40 – 49 (%)  296 (3.9)    354 (1.7)   
50 – 59 (%)  444 (5.1)    800 (2.5)   
60 – 69 (%)  1,069 (6.6)    1,444 (3.3)   
70 – 79 (%)  2,329 (8.7)    3,118 (4.7)   
80 – 89 (%)  3,127 (12.4)    4,926 (6.8)   
90 – 99 (%)  1,209 (16.1)    2,197 (9.6)   
100 + (%)  47 (17.5)    92 (11.6)     19 
Figure 1. Comorbidities of Patients Hospitalized for Community-Acquired Pneumonia 
 
 
 
Error bars indicate 95% confidence intervals. CHF denotes congestive heart failure; DM denotes 
diabetes 
mellitus.   20 
 Figure 2. Mortality Trends   21 
Figure 3. Daily Mortality Rate 
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Figure 4. Hospitalization Costs 
 
 
 